Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dölemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41.
-
Samuel Yao-Ming Ng, M.D.,Ph.D.
-
Daniel J. DeAngelo, Ph.D., M.D.
-
Michael Joseph Eck, Ph.D., M.D.
-
Martha Wadleigh, M.D.
-
Lewis Barry Silverman, M.D.
-
Anthony George Letai, M.D., Ph.D.
-
Richard M. Stone, M.D.
-
Andrew Alan Lane, M.D.,Ph.D.
-
Jeremy Adam Ryan, S.M.
-
David Marc Weinstock, M.D.
-
Stephen Earl Sallan, M.D.
-
Scott J. Rodig, Ph.D., M.D.